Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20679248 | 1.00 | KCNH2 (0.48) | KCNH2 | |
| SCHEMBL18544221 | 0.92 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL18543810 | 0.92 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL18529117 | 0.92 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL20687543 | 0.92 | KCNH2 (0.51) | KCNH2 | |
| Hydrochloric Acid SCHEMBL20679485 | 0.92 | KCNH2 (0.50) | KCNH2 | |
| Hydrochloric Acid SCHEMBL20679504 | 0.92 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL20679479 | 0.92 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL20679499 | 0.92 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL20679486 | 0.91 | KCNH2 (0.55) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3334739-A2 | ANTIBACTERIAL AGENTS COMPRISING A PYRAZINO[2,3-B][1,4]OXAZIN-3-ONE OR A RELATED RING SYSTEM | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-06-20 | — | — | EP | claimed |
| WO-2017029602-A2 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-23 | — | — | WO | claimed |
| US-10683307-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683307-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | KCNH2 2823/4885 |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | MRPL21, CFTR, NRDC | KCNH2 2823/4885 |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | CFTR, MRPL21, CLPP | KCNH2 2998/4885 |
| US-10364254-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | KCNH2 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.